Board of Directors

RE Finance Consulting SA represented by Yves Désiront

CHAIRMAN OF THE BOARD

Yves Désiront is the Managing Partner of a private equity fund based in Luxembourg and was Group CFO from October 2014 until April 2019. He has previously acted as Group CFO of Orco Property Groupand served in various roles at Groupe Bruxelles Lambert and Générale de Banque. Yves Désiront holds a Master’s degree from I.C.H.E.C. Brussels.

Michel Baijot

DIRECTOR & CEO

Michel Baijot, PhD, is a bioengineer with over 25 years of experience in building biologicals businesses, making a significant contribution to strategy, licensing, M&A and technology transfer, with in-depth knowledge of developed and emerging markets

He is currently Board Director of IRE-Elit, the RadioPharma Division of IRE, and Board Director of OncoRadiomics. His previous positions include Executive Director Europe at Serum Institute of India, Head of Cipla Global Vaccine, Chief Business Officer at Janssen/Crucell, Vice President Worldwide Strategic Alliances and Business Development at GlaxoSmithKline Biologicals and Vice President Business Development at Innogenetics. He was Chairman of the Belgian Biotech Association for five years.

François Meurgey

DIRECTOR As managing Partner of Oukelos, François works as an independent consultant in pharmaceutical product strategic marketing. He spent more than 25 years in the biopharmaceutical industry, both in Europe and the United States. He holds both operational and higher management functions including Director of Global Marketing for Prozac® at Eli Lilly, Senior Director of Asia-Pacific Marketing at Merck & Co. and Vice-President of Global Marketing at UCB. François graduated from Reims Management School, and holds a Master’s in International Relations from University of Paris-Sorbonne and an MBA from the Stern School of Business, New York University.

Everard van der Straten

DIRECTOR

Having started at Arthur and Anderson & Co, Everard van der Straten became managing director of Metallo-Chimique Group and then Board Member of the Metallum Group until the end of 2008. Everardholds a Master’s from Solvay Business School and is an active as a private investor.

NOSHAQ SA represented by Philippe Degeer

DIRECTOR

Philippe Degeer developed his career within the American multinational Goodyear Dunlop. After becoming Vice President in Europe, Africa and the Middle East, he oversaw the implementation of innovation processes, international development policies and BtoB and BtoC marketing strategies. He has implemented corporate governance oriented towards investment and growth and participated in the development of various partnerships, mergers, acquisitions and technology transfers. He holds a degree in industrial engineering alongside an MBA from the London Business School. Philippe is Chairman of the Board of Directors of AMOS and is a Board member of Diagenode, Endotools, EyeDPharma and Lasea.

SFPI – FPIM represented by François Fontaine

DIRECTOR François Fontaine is a General Counselor at the Belgian Federal Investment and participation Company (SFPI) since December 2009. He is in charge of investment projects in new technologies, biomedical, real estate, waste, water treatment and energy. François, holds a Master’s in law and tax sciences, he was previously advisor to the tax unit of the Walloon Region in charge of the implementation and transfer of regional taxes.

Harry Welten

DIRECTOR

Harry Welten, MBA, spent more than 20 years in international senior executive functions, 16 of which he served as chief financial officer in biotechnology companies (private and public ). He has been involved in IPO’s, mergers and acquisitions and raised more than CHF 320 million from private and public investors. He holds a degree in banking and finance, a degree in economics and business administration and an MBA (Hons.) from Columbia University, New York. He serves as Chairman of the Board of Directors of Novaremed AG as well as of BiognoSYS AG, and is a member of the Board of Directors of Kanyos, ProteoMediX, Virometix and Horizon Pharma AG. Harry is also a member of the foundation council of HBM Foundation.

Jean-Paul Prieels

DIRECTOR Jean-Paul Prieels received his PhD in Biochemistry from the University of Brussels. He worked at GSK for over 23 year, having most recently served as Senior Vice President of R&D for GSK Vaccines and formerly worked at Smith Kline RIT. Jean-Paul joined the pharmaceutical sector after spending 13 years in academia (ULB, Duke University, ICP-UCL) and 3 years at Oléofina, a subsidiary of Petrofina. In 2011, he left GSK for the biotechnology industry to serve as founder, investor, board member and scientist. He currently serves as a Director of Bone Therapeutics, DNALytics, MastherCell, Ncardia, Paracrine Biologicals and PDC Line Pharma in Belgium, Nouscom in Switzerland, Themis in Austria and Leukocare in Germany. He is also a member of scientific advisory boards of Abivax, CureVac, Imcyse and Vaximm.

Frank Hazevoets

Director and CFO

Frank Hazevoets was an investment banker at several institutions, including ING, and director of strategy and internal growth at AB Inbev. He moved to the healthcare sector in 2007 and was CFO at Tigenix and Promethera Biosciences before joining ASIT biotech in April of 2019 as CFO. He holds a Master of Business Economics and Master of Engineering in Artificial Intelligence and Cognitive Science.